The return on investment of diabetes prevention is not the problem. The maths is not ambiguous. What is broken is the way most insurers are trying to calculate it.
The numbers that already exist
Diabetes-related healthcare costs in the EU total around €104 billion annually. Three quarters of that figure is attributable to complications such as kidney failure, cardiovascular events, neuropathy, amputations, that are, in a significant proportion of cases, preventable. Across Europe, 100,000 diabetes-related lower limb amputations are carried out every year. In Germany, the annual cost per patient undergoing amputation is more than six times higher than a patient with uncomplicated diabetes. That is not a clinical statistic. That is a claims statistic.
Against this, the cost of a structured, evidence-based prevention programme per member is a fraction of a single hospitalisation. The return is arithmetically obvious.
So why is prevention still treated as a discretionary budget line?
The measurement gap
Insurance contracts typically run one to three years. Diabetes complications develop over five to ten. The CFO approving a prevention programme this year will have moved on long before the hospitalisation it prevented would have appeared in the claims data. The problem is not that prevention does not work. It is that most ROI models are not built to capture a return that plays out over a decade.
This is the structural tension that keeps prevention underfunded. Insurers are not irrational, they are optimising for a measurement window that is too short to see the full picture.
The programmes that have broken through this barrier have done so by anchoring on shorter-term proxy indicators: reduced emergency admissions in year one, lower medication escalation rates, improved HbA1c trajectories at six months. The NHS Diabetes Prevention Programme, the largest real-world dataset of its kind, showed a 47% reduction in the odds of progressing to Type 2 diabetes among programme completers. These are not long-horizon projections. They are 24-month outcomes.
Where most programmes fail the ROI test
Here is the part that rarely makes it into the business case: a prevention programme only delivers ROI if the patient stays in it.
Dropout rates in digital health programmes regularly exceed 60% within the first few months. A member who disengages at week six has not received a prevention programme. They have received an onboarding experience. The avoided complication never materialises, the claim reduction never appears, and the insurer's investment produces no return.
This is where the clinical design of the programme becomes a financial decision. Programmes built on behavioural science, specifically; models that account for motivation as a sustained condition rather than a one-time decision, consistently outperform engagement benchmarks over 12 months. Sustained engagement is what translates clinical outcomes into claims outcomes.
How we approach this
Liva's programmes are designed around this reality. The combination of structured digital infrastructure and qualified health coaching, built on the COM-B behavioural model, is specifically intended to address the drop-off problem that undermines programme ROI. When a member stays engaged over 12 months, the biological markers move. When the markers move, the complication risk reduces. And that is when the claims picture starts to change.
If you are building the business case for a prevention programme and want to understand the evidence framework behind this, talk to our team.
